MedTrace Logo

Response-based Treatment of High-risk Neuroblastoma

NCT02771743 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2016-05-24

No results posted yet for this study

Summary

The purpose of this study is to improve outcome of high risk neuroblastoma by tailoring the treatment intensity of tandem high dose chemotherapy according to the treatment response to induction chemotherapy.

Conditions

  • Newly Diagnosed High Risk Neuroblastoma

Interventions

DRUG

Cisplatin

DRUG

Doxorubicin

DRUG

Etoposide

DRUG

Cyclophosphamide

DRUG

Ifosfamide

DRUG

Carboplatin

PROCEDURE

Tandem HDCT/auto-SCT

RADIATION

Radiotherapy

DRUG

Interleukin-2

DRUG

Isotretinoin

RADIATION

MIBG

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Ki Woong Sung, MD, PhD · Samsung Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2020-03-31
Completion
2023-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02771743 on ClinicalTrials.gov